Compare BioNano Genomics Inc (BNGO) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Genuine Parts Company — how do they compare? BioNano Genomics Inc trades at $1.15 (market cap $13.20M), while Genuine Parts Company trades at $122.3 (market cap $16.81B). The key difference: Genuine Parts Company is far larger — about 1273.5× BioNano Genomics Inc's market cap, and Genuine Parts Company pays a 3.48% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | GPC | |
|---|---|---|
Market Cap | $13.20M | $16.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.92 | $149.26 |
52-Week Low | $1.09 | $92.47 |
Enterprise Value | $15.81M | $23.03B |
Dividend Yield | — | 3.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bionano Genomics (BNGO) trades at $1.17, down 2.5% today, but maintains a bullish technical signal with strong moving average support. The company shows improving fundamentals with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable with a -109.95% net margin. Recent positive developments include debt retirement and growing adoption of optical genome mapping technology.
BNGO presents a high-risk, high-reward opportunity with analyst consensus leaning bullish (57% buy ratings). The stock trades at attractive valuation multiples (P/S 0.31, P/B 0.36) but faces execution risks in achieving profitability. Key catalysts include continued technology adoption and potential margin improvement, while persistent losses and competitive pressures remain concerns.
GPC trades at $123.52, down 1.67% over the past day, with technical indicators showing a bullish trend supported by moving averages. The company reported mixed quarterly earnings, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, with Q2 2026 results expected on July 21, 2026. Revenue growth remains modest at $24.3B in 2025, though net income margins have compressed significantly to 0.24%. Analyst sentiment is mixed with a consensus price target of $133.00, representing a 7.7% upside from current levels.
GPC offers potential for moderate upside based on analyst targets and dividend stability, but faces headwinds from declining profitability margins and recent earnings misses. The stock's high P/E ratio of 280.73 suggests premium valuation despite weak earnings growth, while strong cash flow generation and Dividend King status provide some downside protection. Key risks include margin pressure and competitive threats in the automotive parts distribution sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
